Thursday, October 15, 2026 | 11am EDT: Navigating Endpoint Complexity & Safety in Dermatology Clinical Trials

X

Researchers Identify Multi-Action Drug Candidate For Type 2 Diabetes And Bone Disease

Posted on: in News | Life Science News | Pharma News
By:

Related Vitals

Sanofi Opens $925M Toronto Vaccine Facility
The investment expands Sanofi’s Toronto manufacturing footprint and will strengthen Canada’s domestic flu vaccine and pandemic-response capacity.
News

Northway Biotech Opens $70.8M Cell Therapy CDMO Facility in Vilnius, Lithuania
Vilnius, Lithuania, is home to Northway Biotech’s new cell therapy and personalized medicine manufacturing center.
News

From Oxfordshire to Wales: Where UK Life Sciences Investment Is Going in 2026
Cambridge is one of several UK life sciences hubs attracting new investment in R&D, manufacturing and biopharma infrastructure.
News

Bristol Myers Squibb Invests $2.3B in Houston Drug Manufacturing
Bristol Myers Squibb Houston manufacturing
News

Lilly and Resilience Invest $750M to Expand Medicine Production in Ohio
Lilly Resilience Ohio manufacturing investment
Pharmaville: Powering Life Sciences Location Strategy and FDI

Related Webinars

December 11, 2026

Overcome Targeted Alpha Therapy Challenges for Clinical Translation
Hero - Desktop
December 02, 2026

Improve Data Quality With Multicolor Super‑Resolution Imaging
Hero - Desktop
November 19, 2026

Accelerating Early-Stage Oncology Global Drug Development: Connecting West to East
Hero - Desktop
November 11, 2026

Accelerate CQV & Compliance: Why Documentation Quality Drives Operational Readiness
Hero - Desktop
November 10, 2026

Apply Emerging Biomarkers to Improve Neurodegenerative Disease Trials
Hero - Desktop